Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

Naturally, more work is needed. Although GLS -1 agonists have been used in diabetes for 20 years, some of the newer findings ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Zepbound (tirzepatide) is reshaping the competitive landscape in obesity treatment, challenging Novo Nordisk A/S' (NYSE:NVO) ...

at a significantly lower cost — around $250 to $350 per month for tirzepatide, compared to Zepbound's list price of $1,059. With the official shortage over, the FDA has signaled it will crack ...

Specialty drugs, particularly GLP-1 medications like tirzepatide and semaglutide, are key drivers of these rising costs. Aon's analysis reveals that these medications could add 1% to overall ...

Eli Lilly moves to defend FDA's tirzepatide shortage resolution amid criticism over supply issues and compounding pharmacy ...

Cheaper versions of the drug, known as compounded tirzepatide, might be restricted in 2025. Patients could face higher costs and tougher access, and telehealth is racing to adapt. The FDA has ...

Drugs like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro ... For example, a liver transplant can cost upwards of $500,000, a cost that could be avoided by addressing obesity early.

Cheaper versions of the drug, known as compounded tirzepatide, might be restricted in 2025. Patients could face higher costs and tougher access, and telehealth is racing to adapt. The FDA has ...